Welcome to Woomera Therapeutics!
Frank Martin is a Director of the Company and investor in early stage medical technology companies. Frank most recently was President and CEO of NMT Medical. From 2007 through 2008, Frank served as a director and as the founding President and Chief Executive Officer of Corindus Inc., a company that designs, manufactures and commercializes robotic control systems for interventional cardiology. From 2005 until 2007, Frank was Executive Chairman of Cappella Inc., a medical device company that develops, manufactures and commercializes coronary bifurcated stents. From 2000 to 2004, Frank was the Chairman, President and Chief Executive Officer of Florence Medical Ltd which developed and marketed vascular blood flow software and hardware systems to interventional cardiologist. June 1993 to 2000, he was founder, Chairman and Chief Executive Officer of CorMedica Corporation, a private, independent developer and manufacturer of catheter-based navigation systems for use in percutaneous cardiovascular applications. Frank has an extensive background in the medical device industry, having co-founded and managed Advanced Biomedical Instruments from 1979 to 1986 and PLC Systems from 1987 to 1993. Frank started his career with management positions at both Becton Dickinson & Co. and Abbott Laboratories. He holds a A.B. from Boston College, and has completed executive programs at the Harvard Business School.
Dr. North is Founder, President, Chairman of the Board, and Director of the Company. He is a Professor of Physiology and Neurobiology at the Geisel School of Medicine at Dartmouth College, and a Senior Faculty member of the Norris Cotton Cancer Center. Dr. North has been Professor since 1988, and joined the medical school in 1974. From 1979 to 1984 he was recipient of Research Career Development Award from the NIH. Dr. North has served on several Advisory Councils, currently serves on NIH and DOD Study Sections, is a member of the CALGB, the American Association for Cancer Research, the Endocrine Society and AAAS, and is a Fellow of the International Neuropeptide Society. For the past 38 years Dr. North has been conducting research to elucidate the role of vasopressin and associated receptors in the development, growth, and survival of small cell lung cancer, breast cancer, and other common cancers. Dr. North has published extensively with 232 scientific manuscripts and 17 reviews and book chapters, and is inventor on several US Patents. Dr. North holds a Ph.D. in Biochemistry, and in Physiology, from the University of Queensland, Australia, an MS (equiv) from Melbourne University, and an honorary MA degree from Dartmouth College.
John Ballard a is Director of the Company. John is Co-founder and CEO of Radio Propagation Services, Inc. Prior to that, he was Co-founder and CEO of TCI International. In the past 50 years, John has founded or co-founded four technology companies, each of which remains a world leader in its technology. Ballard has authored numerous technical papers and publications. John is a past director of the American Business Conference, Time and Space Processing and the Armed Forces Communications & Electronics Association. In 2001, John cofounded and has since managed Angeli Parvi, a 501(c)3 not for profit dedicated to supporting entrepreneurship at Dartmouth. Angeli Parvi has helped launch ten companies from Dartmouth, (including Woomera) and from 2000 through 2008 showed a 50+% annual rate of return. Some proceeds are retained to support new start-ups, but a significant share is gifted to Dartmouth. John is a member of the Board of Overseers of the Thayer School of Engineering at Dartmouth (Chair 1998-2008). John was named a Sylvanus Thayer Fellow at Dartmouth College in 1988, and was awarded the Robert Fletcher Award in 1998. He holds a M.B.A. from Amos Tuck School of Business, a M.S. from Thayer School of Engineering and an A.B. from Dartmouth College.
Dr. Pang is the Chief Executive Officer since 2013 and Chief Scientific Officer since 2004 and served as CEO from 2004 to October, 2011. He is a Director of the Company. Dr. Pang has over 30 years of experience in the biotechnology and financial industries. Dr. Pang was a Partner at Celemax, LLC. Prior to that, he was the Chief Operating Officer and co-founder of Bioinvest Holding Company, Inc. and served as Executive Vice President at Aberlyn Capital Management Company, Inc., where he managed a portfolio of 40 biotechnology companies. Dr. Pang was a senior executive of several biotechnology companies. From 1991 to 1994, he was the Vice President, Science at Verax Corporation and co-founder of Cellcare, Inc. where he developed a proprietary technology to produce stem cells for bone marrow transplant and managed manufacturing of clinical products under GMP. He specializes in tissue repair and regeneration and helped develop an osteogenic device to treat non-union fractures. Dr. Pang is an inventor or co-inventor in 46 U.S. patents. He holds a Ph.D. from the Medical College of Virginia, Virginia Commonwealth University and a B.S. (Hon.) from Hong Kong University.
Dr. Bartlett is a Director of the Company and has been a Professor of Physiology at the Dartmouth Medical School since 1978, after joining the department in 1971. From 1989-2010 Dr. Bartlett was the Andrew C. Vail Professor (1989 - 2010) and served as Department Chairman for 17 years (1989 - 2005). His extramural service includes membership on the editorial boards of several physiology journals, on several NIH Study Sections and the Veterans Administration Merit Review Board for Respiration. From 1986 to 1990 Dr. Bartlett was a member of the National Heart, Lung and Blood Institute Research Review Committee A (Chairman, 1988-1990), which visited and reviewed major program project grant applicants throughout the country. From 1989 to 1996 Dr. Bartlett was a member of the Physiology Test Committee of the National Board of Medical Examiners (Chairman, 1994-1996). He holds a M.D. from Harvard Medical School and a A.B. from Dartmouth College.